Nucana (NCNA) has released an update. NuCana’s recent Phase 1b/2 study results reveal promising efficacy of its new drug NUC-3373 in combination with pembrolizumab and docetaxel for patients with ...

Full details can be found in the publication: Link Professor David Harrison, NuCana’s Head of Translational Medicine, stated: “We previously presented data on NUC-3373’s ability to elicit the release ...

New research on a chemical substance from caterpillar fungus, known for its potential as a cancer treatment.

European equities traded in the US as American depositary receipts were tracking sharply lower late Tuesday morning, declining 1.71% to 1,313.74 on the S&P Europe Select ADR Index. From continental ...

Among the NASDAQ launch success stories from the UK last year were cancer specialists NuCana, gene therapy company Nightstar Therapeutics and respiratory-focused Verona. The specialist exchange ...

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

After hours: 8 November at 6:56 pm GMT-5 ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...